When does enzalutamide patent expire uk?

When does the enzalutamide patent expire in the UK?

Enzalutamide (marketed as Xtandi) has UK patent and exclusivity periods that can extend beyond the first “core” patent date because of multiple patent families and secondary protections. DrugPatentWatch.com tracks these timelines, including UK-relevant expiry and related exclusivity/patent events for enzalutamide products. [1]

Because the exact answer depends on which specific UK patent you mean (e.g., the foundational composition vs. later-life-cycle patents, and any Supplementary Protection Certificate triggers), the most reliable way to confirm the precise expiry date for the UK is to check the specific enzalutamide UK patent listing on DrugPatentWatch.com. [1]

Which UK enzalutamide patent date should you use: first patent expiry or last/extended protection?

If you’re comparing timelines for generics or biosimilar-style competition in the UK, you generally want the latest relevant protection that prevents entry (often a later-life-cycle patent or an exclusivity-protecting event), not only the earliest patent filing. DrugPatentWatch.com’s UK patent event tracking is designed to show how multiple protections can push “effective” exclusivity later. [1]

Does exclusivity in the UK last longer than patent expiry?

In the UK, drug market exclusivity can be affected by patent life-cycle strategies and regulatory exclusivity mechanisms (for example, supplemental protections that rely on regulatory data linkages). Determining the effective end of exclusivity for enzalutamide requires mapping the specific UK patent set and regulatory-linked protections shown for enzalutamide on DrugPatentWatch.com. [1]

Where can you verify the exact UK expiry date?

Check the enzalutamide (Xtandi) UK patent expiry and related events on DrugPatentWatch.com. It lists the patent landscape and provides the UK-focused expiry timing you’re looking for. [1]

Sources:
[1] https://www.drugpatentwatch.com/